<p>CollPlant Biotechnologies Ltd. reported results for the third quarter (Q3) and nine months (9M) ended September 30, 2025. For Q3 2025, the company recorded revenues of USD 1.4 million. Net loss for the quarter was USD 3.5 million, with basic and diluted net loss per ordinary share at USD 0.27. In the nine-month period, revenues reached USD 4.3 million. Net loss for the nine months was USD 8.3 million, with basic and diluted net loss per ordinary share at USD 0.69. Total operating loss for Q3 2025 was USD 3.5 million, and for the nine-month period was USD 8.3 million. The company reported cash flows from operating activities reflecting a net loss of USD 8.3 million for the nine-month period. CollPlant noted ongoing efforts to expand rhCollagen and BioInk raw material sales in North America, as well as cost reduction initiatives to extend its cash runway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collplant Biotechnologies Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN33339) on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

CLGN

<p>CollPlant Biotechnologies Ltd. reported a 35% reduction in net loss for the nine months ended September 30, 2025, totaling USD 8.3 million. Q3 2025 revenues were USD 1.4 million with a net loss of USD 3.5 million. The company is focusing on expanding rhCollagen and BioInk sales in North America and implementing cost reduction initiatives.</p>

Collplant Biotechnologies 9M 2025 net loss narrows 35% to USD 8.3 million